OptimizeRx Corporation reaffirmed financial guidance for the year 2022. The company is reaffirming its full year financial outlook for 2022 and continues to expect net revenues of $80 million to $85 million, representing year-over-year growth of 31% to 39%, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.72 USD | -2.82% | -9.43% | -18.10% |
05-14 | Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | OptimizeRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.10% | 220M | |
+27.72% | 426B | |
+30.17% | 276B | |
+3.61% | 135B | |
+7.43% | 92.01B | |
+25.57% | 89.16B | |
+66.90% | 58.86B | |
+12.06% | 45.03B | |
+21.48% | 34.77B | |
-10.69% | 31.93B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Reaffirms Financial Guidance for the Year 2022